Results 131 to 140 of about 25,328 (173)

Pharmacovigilance analysis of immune checkpoint inhibitor-associated optic nerve toxicity based on the FAERS database. [PDF]

Front Pharmacol
Bao H, Lin L, Huan W, Bao H, Su H, Luo X, Deng C, Hu J, Cao X, Wu X.   +9 more
europepmc   +1 more source

Real-world analysis in patients with limited-stage small-cell lung cancer who received durvalumab after concurrent chemoradiotherapy. [PDF]

Transl Lung Cancer Res
Yu J, Yang X, Shan J, Yang D, Chang X, Jiang L, Long L, Teng Y, Dong X, Yu R, Yu H, Zhao J, Ma S, Shi A.   +13 more
europepmc   +1 more source

Real-World Survival Outcomes Following Chemoradiotherapy with or Without Durvalumab in PD-L1-Defined Subgroups of Stage III Unresectable NSCLC. [PDF]

Curr Oncol
Selke J, Dzierma Y, Manda K, Hildebrandt G, Frerker B, Kalata P, Ackermann C, Bock F.   +7 more
europepmc   +1 more source

DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy. [PDF]

J Immunother Cancer
Zhao Y, Wang Q, Xiao B, Jia J, Liu X, Ma S, Liu H, Zhou T, Yang Y, Fang W, Zhang L, Huang Y.   +11 more
europepmc   +1 more source

MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition. [PDF]

Clin Cancer Res
Schlaak M, Cimminiello C, Pigozzo J, Lee J, Grabbe S, Rutkowski P, Mackiewicz J, Tsai KK, Ascierto PA, Mandalà M, Carnevale-Schianca F, Haferkamp S, Atkinson V, Hassel JC, Sandhu S, Sharfman W, Dean E, Noor U, Iyer S, Rabbie R, Ribas A.   +20 more
europepmc   +1 more source

AdvanTIG-301: a phase III study of ociperlimab plus tislelizumab and concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer. [PDF]

J Immunother Cancer
Xing L, Kato T, Levy A, Loo BW, Spira AI, Wang J, Meng X, Pang Q, Badin F, Wang H, Dómine Gómez M, Wang Y, Chen Y, Yao B, Yang L, Yu J, Peters S.   +16 more
europepmc   +1 more source

Response to the Letter Regarding "Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial". [PDF]

J Gastroenterol Hepatol
Tada T, Matono T, Kumada T.
europepmc   +1 more source

Real-world treatment patterns and outcomes of chemo-immunotherapy with or without radiotherapy in extensive-stage small cell lung cancer: the durvalumab expanded access cohort. [PDF]

Front Oncol
Janzic U, Shalata W, Unk M, Terglav AS, Shirron N, Daher S, Moskovitz M, Merimsky O, Garrido P, Lopes M, Araujo D, Shantzer T, Gantz-Sorotsky H, Rotem O, Urban D, Chmielewska I, Barroso A, Zer A.   +17 more
europepmc   +1 more source

Durable Response to Durvalumab in Occult Small-Cell Lung Cancer With Immune Checkpoint Inhibitor-Related Inflammatory Arthritis With Polymyalgia Rheumatica-Like Features. [PDF]

Geriatr Gerontol Int
Fujimi A, Yamauchi N, Sato K, Nagamachi Y, Nishisato T, Takada K.   +5 more
europepmc   +1 more source